Today patients with mild to moderate Alzhiemer's disease (AD) have a treatment approach choice: oral or transdermal delivery. The aim of this review was to provide a concise, comprehensive overview of the clinically relevant safety, tolerability and efficacy information available for the rivastigmine transdermal system. Relevant articles were identified through a MEDLINE search of publications ...

Background: The aim of this prospective randomized clinical trial was to determine the optimal endometrial preparation protocol by comparing the clinical outcome of two methods of endometrial preparation in FET cycles, that is, oral estradiol and 17 β-estradiol transdermal patch. Materials and Methods: A total number of 90 patients were scheduled for FET. In the study group (n=45), 17-B estradi...

1) Study's objective is "To assess rotigotine transdermal patch for the perioperative management of moderate to severe RLS". To assess what? Efficacy? Feasibility of use? The objective of this posthoc analysis was to assess the feasibility of use of rotigotine transdermal patch for the perioperative management of moderate to severe RLS. Efficacy data for the entire study population, including p...

BACKGROUND The purpose of this study was to develop a transdermal ligustrazine patch containing a stable formulation and with good entrapment efficiency, release rate, and transdermal absorption. METHODS Ligustrazine ethosomes were prepared by ethanol injection-sonication, with entrapment efficiency as an indicator. Using acrylic resin as the primary constituent, the ligustrazine ethosome pat...

PURPOSE To determine whether (1) tailored nicotine patch therapy that is based on smoking rate can be carried out in a multisite oncology investigative group practice setting, (2) long-term use of bupropion reduces the rate of relapse to smoking in smokers who stop smoking with nicotine patch therapy, and (3) bupropion can initiate smoking abstinence among smokers who have failed to stop smokin...

Adolescent smokers (N = 211) were randomized to 1 of 2 groups: (a) nicotine patch plus bupropion SR (sustained release; 150 mg per day) or (b) nicotine patch plus placebo. Group skills training sessions were conducted each week by research staff. Abstinence rates at Weeks 10 and 26 were as follows: (a) patch plus bupropion, 23% and 8%, (b) patch plus placebo, 28% and 7%. Despite the lack of a t...